Ascletis Gains China Market Rights from Janssen to a Clinical Stage HIV Protease Inhibitor

The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in .

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Ascletis-Gains-China-Market-Rights-from-Janssen-to/ArticleNewsFeed/Article/detail/811919?ref=25